

# MATHEMATICA

## Policy Research

DATA TYPE SUMMARY	DATA TYPE
Abstractor and Site Information	Name
	Date
	Type 1 Site ID
	Type 2 Site ID
Demographic information	Client Identifier
	Age
	Gender
Initial HIV diagnosis	Month and year of initial HIV diagnosis
Outpatient medical visit	Dates of all medical visits.
	Medical visit data source
Prescription of ART	Dates of ART prescriptions
	Type of ART prescriptions
	ART prescription data source
Viral load suppression	Dates of viral load lab tests
	Results of viral load lab tests
	Viral load data source

\* This value will be pre-populated from the 2017 RSR.

**Public Burden Statement:** An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a unique OMB control number. The OMB control number for this project is 0915-xxxx. Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, reviewing and collecting the data, and reviewing and completing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Field Office, Room 14N136B, Rockville, Maryland, 20857.

<b>INSTRUCTIONS</b>
The name of the person doing chart abstraction/data collection
The date of data collection/medical chart abstraction
The Type 1 provider side ID
The Type 2 provider side ID
Client's eUCI or encrypted client identifier*
Client's current age*
Client's current gender*
Indicate month and year, if known, of initial HIV diagnosis
Record dates of all outpatient medical visits for client in 2018. Medical visits are defined as the provision of professional diagnosis by a licensed physician, physician's assistant, clinical nurse specialist, or nurse practitioner in an outpatient setting (not a hospital, inpatient treatment center), consistent with HHS guidelines and including access to antiretroviral and other drug therapies, including opportunistic infections and combination antiretroviral therapies. Allowable services include: Diagnostic testing • Early intervention and screening • Practitioner examination, medical history taking, diagnosis and treatment of common physical and mental conditions • Medication therapy • Education and counseling on health issues • Well-baby care • Continuing care and management of chronic conditions • HIV-related specialty care (includes all medical subspecialties even ophthalmic and optometric services)
Indicate whether the information found in the medical record regarding the client's medical visits is a primary or secondary source
Enter dates of all ART prescriptions in 2018.
Select brand or generic name of all ART medications prescribed. See list of HIV medicines approved by FDA.
Indicate whether the information found in the medical record regarding the client's ART prescription is a primary or secondary source
Enter dates of all viral load lab tests ordered in 2018.
Indicate results (in copies/ml) of all lab tests.
Indicate whether the information found in the client's medical record regarding the viral load test is a primary or secondary source

## Drug Class

### Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (N=6)

NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself.

### Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (N=6)

NNRTIs bind to and later alter reverse transcriptase, an enzyme HIV needs to make copies of itself.

### Protease Inhibitors (PIs) (N = 6)

PIs block HIV protease, an enzyme HIV

### Fusion Inhibitors (N 1)

Fusion inhibitors block HIV from entering the CD4 cells of

the CCR5 Antagonists (N=1)

CCR5 antagonists block CCR5

coreceptors on the surface of

Integrase Inhibitors (N= 2)

Integrase inhibitors block HIV integras

Post-Attachment Inhibitors (N = 1)

Post-attachment inhibitors block CD4 receptors on the surface of certain immune cells that HIV needs to enter


Pharmacokinetic Enhancers (N = 1)

Pharmacokinetic enhancers are used in HIV treatment to

Increase the effectiveness of

Combination HIV Medicines (N = 2)

Combination HIV medicines contain two or more HIV medicines from one or more drug classes.



<https://aidsinfo.nih.gov/understandin>

Generic Name (Other names and acronyms)	Brand Name
<b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (N = 5)</b>	
<a href="#">abacavir</a> (abacavir sulfate, ABC)	Ziagen
<a href="#">emtricitabine</a> (FTC)	Emtriva
<a href="#">lamivudine</a> (3TC)	Epivir
<a href="#">tenofovir disoproxil fumarate</a> (tenofovir DF, TDF)	Viread
<a href="#">zidovudine</a> (azidothymidine, AZT, ZDV)	Retrovir
<b>Nucleoside Analog Reverse Transcriptase Inhibitors (NNRTIs) (N = 5)</b>	
<a href="#">doravirine</a> (DOR)	Pifeltro
<a href="#">efavirenz</a> (EFV)	Sustiva
<a href="#">etravirine</a> (ETR)	Intelence
<a href="#">nevirapine</a> (extended-release nevirapine, NVP)	Viramune Viramune XR (extended release)
<a href="#">rilpivirine</a> (rilpivirine hydrochloride, RPV)	Edurant
<b>Protease Inhibitors (PIs) (N = 7)</b>	
<a href="#">atazanavir</a> (atazanavir sulfate, ATV)	Reyataz
<a href="#">darunavir</a> (darunavir ethanolate, DRV)	Prezista
<a href="#">fosamprenavir</a> (fosamprenavir calcium, FOS-APV, FPV)	Lexiva
<a href="#">ritonavir</a> (RTV) <i>*Although ritonavir is a PI, it is generally used as a pharmacokinetic enhancer as recommended in the <a href="#">Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV</a> and the <a href="#">Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</a>.</i>	Norvir
<a href="#">saquinavir</a> (saquinavir mesylate, SQV)	Invirase
<a href="#">tipranavir</a> (TPV)	Aptivus
<b>Integrase Inhibitors (INSTIs) (N = 2)</b>	
<a href="#">enfuvirtide</a> (T-20)	Fuzeon
<a href="#">maraviroc</a>	Selzentry

(MVC)	
<a href="#">dolutegravir</a> (DTG, dolutegravir sodium)	Tivicay
<a href="#">raltegravir</a> (raltegravir potassium, RAL)	Isentress Isentress HD
<a href="#">ibalizumab</a> (Hu5A8, IBA, Ibalizumab-uiyk, TMB-355, TNX-355)	Trogarzo
<a href="#">cobicistat</a> (COBI)	Tybost
<a href="#">abacavir and lamivudine</a> (abacavir sulfate / lamivudine, ABC / 3TC)	Epzicom
<a href="#">abacavir, dolutegravir, and lamivudine</a> (abacavir sulfate / dolutegravir sodium / lamivudine, ABC / DTG / 3TC)	Triumeq
<a href="#">abacavir, lamivudine, and zidovudine</a> (abacavir sulfate / lamivudine / zidovudine, ABC / 3TC / ZDV)	Trizivir
<a href="#">atazanavir and cobicistat</a> (atazanavir sulfate / cobicistat, ATV / COBI)	Evotaz
<a href="#">bictegravir, emtricitabine, and tenofovir alafenamide</a> (bictegravir sodium / emtricitabine / tenofovir alafenamide fumarate, BIC / FTC / TAF)	Biktarvy
<a href="#">darunavir and cobicistat</a> (darunavir ethanolate / cobicistat, DRV / COBI)	Prezcobix
<a href="#">darunavir, cobicistat, emtricitabine, and tenofovir alafenamide</a> (darunavir ethanolate / cobicistat / emtricitabine / tenofovir AF, darunavir ethanolate / cobicistat / emtricitabine / tenofovir alafenamide, darunavir / cobicistat / emtricitabine / tenofovir AF, darunavir / cobicistat / emtricitabine / tenofovir alafenamide fumarate, DRV / COBI / FTC / TAF)	Symtuza
<a href="#">dolutegravir and rilpivirine</a> (dolutegravir sodium / rilpivirine hydrochloride, DTG / RPV)	Juluca
<a href="#">doravirine, lamivudine, and tenofovir disoproxil fumarate</a> (doravirine / lamivudine / TDF, doravirine / lamivudine / tenofovir DF, DOR / 3TC / TDF)	Delstrigo
<a href="#">efavirenz, emtricitabine, and tenofovir disoproxil fumarate</a> (efavirenz / emtricitabine / tenofovir DF, EFV / FTC / TDF)	Atripla
<a href="#">efavirenz, lamivudine, and tenofovir disoproxil fumarate</a> (EFV / 3TC / TDF)	Symfi
<a href="#">efavirenz, lamivudine, and tenofovir disoproxil fumarate</a> (EFV / 3TC / TDF)	Symfi Lo
<a href="#">elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide</a> (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide fumarate, EVG / COBI / FTC / TAF)	Genvoya
<a href="#">elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate</a> (QUAD, EVG / COBI / FTC / TDF)	Stribild

<a href="#">emtricitabine, rilpivirine, and tenofovir alafenamide</a> (emtricitabine / rilpivirine / tenofovir AF, emtricitabine / rilpivirine / tenofovir alafenamide fumarate, emtricitabine / rilpivirine hydrochloride / tenofovir AF, emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide, emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide fumarate, FTC / RPV / TAF)	Odefsey
<a href="#">emtricitabine, rilpivirine, and tenofovir disoproxil fumarate</a> (emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate, emtricitabine / rilpivirine / tenofovir, FTC / RPV / TDF)	Complera
<a href="#">emtricitabine and tenofovir alafenamide</a> (emtricitabine / tenofovir AF, emtricitabine / tenofovir alafenamide fumarate, FTC / TAF)	Descovy
<a href="#">emtricitabine and tenofovir disoproxil fumarate</a> (emtricitabine / tenofovir DF, FTC / TDF)	Truvada
<a href="#">lamivudine and tenofovir disoproxil fumarate</a> (Temixys, 3TC / TDF)	Cimduo
<a href="#">lamivudine and zidovudine</a> (3TC / ZDV)	Combivir
<a href="#">lopinavir and ritonavir</a> (ritonavir-boosted lopinavir, LPV/r, LPV / RTV)	Kaletra

[g-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines/](http://g-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines/)



## FDA Approval Date

17-Dec-98

2-Jul-03

17-Nov-95

26-Oct-01

19-Mar-87

30-Aug-18

17-Sep-98

18-Jan-08

21-Jun-96

25-Mar-11

20-May-11

20-Jun-03

23-Jun-06

20-Oct-03

1-Mar-96

6-Dec-95

22-Jun-05

13-Mar-03

6-Aug-07

August 13, 2013
12-Oct-07
May 26, 2017
6-Mar-18
24-Sep-14
2-Aug-04
22-Aug-14
14-Nov-00
29-Jan-15
7-Feb-18
29-Jan-15
July 17, 2018
21-Nov-17
30-Aug-18
12-Jul-06
22-Mar-18
5-Feb-18
5-Nov-15
27-Aug-12

1-Mar-16

10-Aug-11

4-Apr-16

2-Aug-04

28-Feb-18

27-Sep-97

15-Sep-00

# MATHEMATICA Policy Research

**Public Burden Statement:** An agency may not conduct or collect information from you unless it displays a unique identification number for this project is 0915-xxxx. Public reporting burden for this collection of information is estimated to average 15 minutes per response, including reviewing the collection of information, providing the information, reviewing and completing the collection of information, and completing and reviewing the collection of information, to HRSA Reports Clearance Officer, 5600 Fish

Abstractor and provider information			
Abstractor name	Abstraction date	Type 1 provider encrypted ID	Type 2 provider encrypted ID

ct or sponsor, and a person is not required to respond to, a collection of information unless it displays a curr  
; burden for this collection of information is estimated to average xx hours per response, including the time  
of information. Send comments regarding this burden estimate or any other aspect of this collection of infc  
ers Lane, Room 14N136B, Rockville, Maryland, 20857.

Demographic information (for validation of record)			Initial HIV diagnosis
Client encrypted ID (eUCI)	Client age	Client gender (current)	Month and year of initial HIV diagnosis

rently valid OMB control number. The OMB control  
for reviewing instructions, searching existing data  
ormation, including suggestions for reducing this

OMB NUMBER: 0915-XXXX  
EXPIRATION DATE: XX/XX/20XX

<b>HIV medical visits</b>		<b>Prescription of ART</b>	
Dates of outpatient medical visits (see definition)	Medical visit data source	Dates of ART prescriptions	Types of ART prescribed

	<b>Viral load tests and results</b>		
ART prescription data source	Dates of viral load lab tests	Results of viral load lab tests	Viral load data source

<b>Notes</b>
Additional Information from the Abstractor